Patient Guide: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 57 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT04442022
Status: 🟢 Enrolling Now
Condition: Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase: PHASE2, PHASE3

Where You Can Participate

This study is available at 57 locations across the country.

Top locations include:
  • • Chandler, Arizona
  • • Tucson, Arizona
  • • Cerritos, California
  • • And 54 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma - Join Clinical Trial NCTNCT04442022

How to Join This Clinical Trial - NCTNCT04442022

Learn how to participate in this PHASE2, PHASE3 trial studying an investigational therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Relapsed/Refractory Diffuse Large B-cell Lymphoma. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2, PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT04442022 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 57 locations. Find a study site near you:

Clinical Research Site

Chandler, Arizona 85224 - United States

Status: COMPLETED

Clinical Research Site

Tucson, Arizona 85711 - United States

Status: RECRUITING

Clinical Research Site

Cerritos, California 90703 - United States

Status: RECRUITING

Clinical Research Site

Indianapolis, Indiana 46260 - United States

Status: WITHDRAWN

Clinical Research Site

Louisville, Kentucky 40207 - United States

Status: RECRUITING

Clinical Research Site

New Orleans, Louisiana 70112 - United States

Status: WITHDRAWN

Clinical Research Site

Baltimore, Maryland 21201 - United States

Status: RECRUITING

Clinical Research Site

Las Vegas, Nevada 89169 - United States

Status: WITHDRAWN

Clinical Research Site

Albuquerque, New Mexico 87106 - United States

Status: WITHDRAWN

Clinical Research Site

Stony Brook, New York 11794 - United States

Status: RECRUITING

And 47 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2, PHASE3 clinical trial for Relapsed/Refractory Diffuse Large B-cell Lymphoma:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships